Suchergebnisse
Puma Biotechnology. 424-248-6500 ir@pumabiotechnology.com. David Schull Russo Partners, LLC. david.schull@russopartnersllc.com. Investor Email Alerts.
PUMA BIOTECHNOLOGY, INC. is a biopharmaceutical company with a focus on the development and commercialization of in-novative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357 in 2011.
At Puma Biotechnology, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
17. Juli 2024 · Puma Biotech surges amid Wyeth victory in Tagrisso patent case: 6: Seeking Alpha: 03.05. Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript: 4: Insider Monkey: 03.05.
29. Feb. 2024 · Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2023 compared to the fourth quarter and full year 2022. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial ...
5. Jan. 2021 · Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011.
Get a real-time Puma Biotechnology, Inc. (PBYI) stock price quote with breaking news, financials, statistics, charts and more.
